Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2024 Sep 18

PMID 39290805

Authors

Abdelrahman Elsayed

Basant Elsayed

Mohamed Elmarasi

Ahmed Adel Elsabagh

Engy Elsayed

Ibrahim Elmakaty

Mohamed Yassin

Affiliations

Soon will be listed here.

Abstract

Hematopoietic cell transplantation (HCT) is a well-established procedure that has become a therapeutic mainstay for various hematological conditions. Prolonged thrombocytopenia following HCT is associated with a significant risk of morbidity and mortality, yet no universally recognized treatment protocol exists for such a complication. First-generation thrombopoietin receptor (TpoR) agonists as well as second-generation agents are known for their role in enhancing platelet production, and their use is expanding across various thrombocytopenic conditions. Therefore, we conducted this comprehensive review of the literature to provide an updated evaluation of the use of TpoR agonists and explore their efficacy and safety in the treatment of extended post-HCT thrombocytopenia. The literature search was conducted using PubMed database from 1996 through December 2023, using a predefined strategy with medical subject headings terms. We identified 64 reports on the utility of TpoR agonists, five of them were randomized controlled trials and the rest were retrospective observational studies and case series, with a total number of 1730 patients. Second-generation TpoR agonists appear more convenient than subcutaneous recombinant human thrombopoietin (rhTpo) as they can be orally administered and exhibit similar efficacy in platelet recovery, as indicated by recent trial results. Among these agents, avatrombopag, unlike eltrombopag, does not require any dietary restrictions, which could be more favorable for patients. However, eltrombopag remains the most extensively studied agent. TpoR agonists had promising effects in the treatment of post-HCT thrombocytopenia with a good safety profile so far, highlighting the potential benefit of their use.

References

Buchbinder D, Hsieh L, Krance R, Nugent D . Successful treatment of post-transplant thrombocytopenia with romiplostim in a pediatric patient with X-linked chronic granulomatous disease. Pediatr Transplant. 2014; 18(7):E252-4. DOI: 10.1111/petr.12325. View

Majhail N . Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10(4):220-227. PMC: 5925745. DOI: 10.1016/j.hemonc.2017.05.009. View

Calmettes C, Vigouroux S, Tabrizi R, Milpied N . Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011; 46(12):1587-9. DOI: 10.1038/bmt.2011.179. View

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S . Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(5):919-24. DOI: 10.1016/j.bbmt.2016.01.018. View

Yaman Y, Elli M, Sahin S, Ozdilli K, Bilgen H, Bayram N . Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatr Transplant. 2021; 25(5):e13962. DOI: 10.1111/petr.13962. View

Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M . Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2010; 377(9763):393-402. DOI: 10.1016/S0140-6736(10)60959-2. View

Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A . Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019; 70(4):1336-1348. PMC: 6849531. DOI: 10.1002/hep.30561. View

Fenaux P, Muus P, Kantarjian H, Lyons R, Larson R, Sekeres M . Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017; 178(6):906-913. PMC: 5600084. DOI: 10.1111/bjh.14792. View

Yang C, Li Y, Kuter D . The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999; 105(2):478-85. View

10.

Wolff S, Herzig R, Lynch J, Ericson S, Greer J, Stein R . Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant. 2001; 27(3):261-8. DOI: 10.1038/sj.bmt.1702772. View

11.

Xu X, Niu X, Guo Z, He H, Qiu D, Liu C . [Effects of recombinant human interleukin 11 on hematological malignancy after allogeneic hematopoietic cell transplantation]. Zhonghua Yi Xue Za Zhi. 2011; 91(2):100-2. View

12.

Thomas E, Storb R, Clift R, Fefer A, Johnson F, Neiman P . Bone-marrow transplantation (first of two parts). N Engl J Med. 1975; 292(16):832-43. DOI: 10.1056/NEJM197504172921605. View

13.

Gu J, Liu J, Li X, Zou W, Huang B, Chen M . Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Cancer Med. 2021; 10(21):7641-7649. PMC: 8559510. DOI: 10.1002/cam4.4294. View

14.

Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F . AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009; 82(4):247-54. DOI: 10.1111/j.1600-0609.2008.01198.x. View

15.

Sivakumaran M, Hutchinson R, Pringle H, Graham S, Primrose L, Wood J . Thrombocytopenia following autologous bone marrow transplantation: evidence for autoimmune aetiology and B cell clonal involvement. Bone Marrow Transplant. 1995; 15(4):531-6. View

16.

Zheng L, Liang M, Zeng X, Li C, Zhang Y, Chen X . Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals. Basic Clin Pharmacol Toxicol. 2017; 121(5):414-422. DOI: 10.1111/bcpt.12815. View

17.

Xu Y, Song X, Du F, Zhao Q, Liu L, Ma Z . A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. J Cancer. 2018; 9(24):4718-4725. PMC: 6299384. DOI: 10.7150/jca.26690. View

18.

Al-Samkari H, Parnes A, Goodarzi K, Weitzman J, Connors J, Kuter D . A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020; 106(4):1148-1157. PMC: 8018116. DOI: 10.3324/haematol.2020.251900. View

19.

Broudy V, Lin N . AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2003; 25(2):52-60. DOI: 10.1016/j.cyto.2003.05.001. View

20.

Vigon I, Mornon J, Cocault L, Mitjavila M, Tambourin P, Gisselbrecht S . Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992; 89(12):5640-4. PMC: 49348. DOI: 10.1073/pnas.89.12.5640. View